Mass malaria treatment trial aims to wipe out hidden infections in ghanaian communities

NCT ID NCT07389057

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will give a combination of two malaria drugs (dihydroartemisinin-piperaquine and primaquine) to entire communities in Ghana every two months for two years. The goal is to see if this approach can reduce the number of people carrying malaria parasites, even those with no symptoms. About 9,000 people aged 3 months and older will take part, and the results will help guide national malaria policy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pokrom sub district

    RECRUITING

    Accra, Eastern Region, 233, Ghana

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••